Ginsenoside Rb1 attenuates agonist-induced contractile response via inhibition of store-operated calcium entry in pulmonary arteries of normal and pulmonary hypertensive rats

Cellular Physiology and Biochemistry

Volumn 35, Issue 4, 2015, Pages 1467-1481

  Wang, Rui Xing ^a   He, Rui Lan ^a   Jiao, Hai Xia ^a   Dai, Mao ^a   Mu, Yun Ping ^a   Hu, Ying ^a   Wu, Zhi Juan ^a   Sham, James S K ^a,b   Lin, Mo Jun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hypoxia; Ginsenoside Rb1; Monocrotaline; Pulmonary hypertension; Store operated calcium entry

Indexed keywords

CALCIUM ION; CYCLOPIAZONIC ACID; ENDOTHELIN 1; GADOLINIUM; GINSENOSIDE RB 1; MONOCROTALINE; NIFEDIPINE; CALCIUM; CALCIUM CHANNEL; GINSENOSIDE; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY MUSCLE; ARTICLE; CALCIUM TRANSPORT; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; LUNG VASOCONSTRICTION; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; STORE OPERATED CALCIUM ENTRY; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MUSCLE CONTRACTION; PANAX; PATHOLOGY; SARCOPLASMIC RETICULUM; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

PANAX GINSENG; RATTUS;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CELL HYPOXIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GADOLINIUM; GINSENOSIDES; HYPERTENSION, PULMONARY; INDOLES; MALE; MONOCROTALINE; MUSCLE CONTRACTION; MYOCYTES, SMOOTH MUSCLE; NIFEDIPINE; PANAX; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM;

EID: 84925434868     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373966     Document Type: Article

References (72)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
3. Firth AL, Won JY, Park WS: Regulation of ca(2+) signaling in pulmonary hypertension. Korean J Physiol Pharmacol 2013;17:1-8.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G: Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
5. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X, Parent F, Savale L, Natali D, Gunther S, Chaouat A, Chabot F, Cordier JF, Habib G, Gressin V, Jing ZC, Souza R, Simonneau G: Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-555.
6. Quan HY, Yuan HD, Jung MS, Ko SK, Park YG, Chung SH: Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Int J Mol Med 2012;29:73-80.
7. Wei X, Chen J, Su F, Su X, Hu T, Hu S: Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int Immunol 2012;24:465-471.
8. Kim HJ, Kim P, Shin CY: A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013;37:8-29.
9. Attele AS, Wu JA, Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-1693.
10. Lan TH, Xu ZW, Wang Z, Wu YL, Wu WK, Tan HM: Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition. Biochem Pharmacol 2011;82:148-155.
11. Chai H, Dong Y, Wang X, Zhou W: Ginsenoside Rb1 attenuates homocysteine-augmented guidewire injury-induced intimal hyperplasia in mice. J Surg Res 2009;157:193-198.
12. Zhang S, Deng J, Gao Y, Yang DL, Gong QH, Huang XN: Ginsenoside Rb(1) inhibits the carotid neointimal hyperplasia induced by balloon injury in rats via suppressing the phenotype modulation of vascular smooth muscle cells. Eur J Pharmacol 2012;685:126-132.
13. Chai H, Schultz G, Aghaie K, Zhou W: In vivo assessment of the effects of ginsenoside Rb1 on intimal hyperplasia in ApoE knockout mice. J Surg Res 2010;162:26-32.
14. Yu J, Eto M, Akishita M, Kaneko A, Ouchi Y, Okabe T: Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor. Biochem Biophys Res Commun 2007;353:764-769.
15. Li QY, Chen L, Fu WH, Li ZD, Wang B, Shi XJ, Zhong MK: Ginsenoside Rb1 inhibits proliferation and inflammatory responses in rat aortic smooth muscle cells. J Agric Food Chem 2011;59:6312-6318
16. Wang XF, Liu XJ, Zhou QM, Du J, Zhang TL, Lu YY, Su SB: Ginsenoside rb1 reduces isoproterenol-induced cardiomyocytes apoptosis in vitro and in vivo. Evid Based Complement Alternat Med 2013;2013:454389.
17. Li J, Shao ZH, Xie JT, Wang CZ, Ramachandran S, Yin JJ, Aung H, Li CQ, Qin G, Vanden Hoek T, Yuan CS: The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch Pharm Res 2012;35:1259-1267.
18. Kong HL, Li ZQ, Zhao YJ, Zhao SM, Zhu L, Li T, Fu Y, Li HJ: Ginsenoside Rb1 protects cardiomyocytes against CoCl2-induced apoptosis in neonatal rats by inhibiting mitochondria permeability transition pore opening. Acta Pharmacol Sin 2010;31:687-695.
19. Kong HL, Wang JP, Li ZQ, Zhao SM, Dong J, Zhang WW: Anti-hypoxic effect of ginsenoside Rbl on neonatal rat cardiomyocytes is mediated through the specific activation of glucose transporter-4 ex vivo. Acta Pharmacol Sin 2009;30:396-403.
20. Jiang QS, Huang XN, Yang GZ, Jiang XY, Zhou QX: Inhibitory effect of ginsenoside Rb1 on calcineurin signal pathway in cardiomyocyte hypertrophy induced by prostaglandin F2alpha. Acta Pharmacol Sin 2007;28:1149-1154.
21. Xia R, Zhao B, Wu Y, Hou JB, Zhang L, Xu JJ, Xia ZY: Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats. J Biomed Biotechnol 2011;2011:767930.
22. Wang Z, Li M, Wu WK, Tan HM, Geng DF: Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction. Cardiovasc Drugs Ther 2008;22:443-452.
23. Zhao H, Lv D, Zhang W, Dong W, Feng J, Xiang Z, Huang L, Qin C, Zhang L: Ginsenoside-Rb1 attenuates dilated cardiomyopathy in cTnT(R141W) transgenic mouse. J Pharmacol Sci 2010;112:214-222.
24. Jiang QS, Huang XN, Dai ZK, Yang GZ, Zhou QX, Shi JS, Wu Q: Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat. J Ethnopharmacol 2007;111:567-572.
25. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF: Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-1032.
26. Shimoda LA, Sham JS, Sylvester JT: Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 2000;49:549-560.
27. Liu DH, Chen YM, Liu Y, Hao BS, Zhou B, Wu L, Wang M, Chen L, Wu WK, Qian XX: Rb1 protects endothelial cells from hydrogen peroxide-induced cell senescence by modulating redox status. Biol Pharm Bull 2011;34:1072-1077.
28. Xia Y, Yang XR, Fu Z, Paudel O, Abramowitz J, Birnbaumer L, Sham JS: Classical transient receptor potential 1 and 6 contribute to hypoxic pulmonary hypertension through differential regulation of pulmonary vascular functions. Hypertension 2014;63:173-180.
29. Sun H, Xia Y, Paudel O, Yang XR, Sham JS: Chronic hypoxia-induced upregulation of Ca2+-activated Cl-channel in pulmonary arterial myocytes: a mechanism contributing to enhanced vasoreactivity. J Physiol 2012;590:3507-3521.
30. MacLean MR, Morecroft I: Increased contractile response to 5-hydroxytryptamine1-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br J Pharmacol 2001;134:614-620.
31. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I: 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996;119:917-930.
32. Liu JQ, Erbynn EM, Folz RJ: Chronic hypoxia-enhanced murine pulmonary vasoconstriction: role of superoxide and gp91phox. Chest 2005;128:594S-596S.
33. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ: Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 2006;290:L2-10.
34. Lin MJ, Leung GP, Zhang WM, Yang XR, Yip KP, Tse CM, Sham JS: Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004;95:496-505.
35. Liu XR, Liu Q, Chen GY, Hu Y, Sham JS, Lin MJ: Down-regulation of TRPM8 in pulmonary arteries of pulmonary hypertensive rats. Cell Physiol Biochem 2013;31:892-904.
36. Liu XR, Zhang MF, Yang N, Liu Q, Wang RX, Cao YN, Yang XR, Sham JS, Lin MJ: Enhanced store-operated Ca(2)+ entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Cell Physiol 2012;302:C77-87.
37. Shimoda LA, Sham JS, Shimoda TH, Sylvester JT: L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. Am J Physiol Lung Cell Mol Physiol 2000;279:L884-894.
38. Yang X, Xiong X, Wang H, Wang J: Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies. Evid Based Complement Alternat Med 2014;2014:204840.
39. Wu Y, Xia ZY, Dou J, Zhang L, Xu JJ, Zhao B, Lei S, Liu HM: Protective effect of ginsenoside Rb1 against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Mol Biol Rep 2011;38:4327-4335.
40. Wang X, Chai H, Lin PH, Yao Q, Chen C: Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009;174:771-781.
41. Pan C, Huo Y, An X, Singh G, Chen M, Yang Z, Pu J, Li J: Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. Vascul Pharmacol 2012;56:150-158.
42. Kim HS, Lee JH, Goo YS, Nah SY: Effects of ginsenosides on Ca2+ channels and membrane capacitance in rat adrenal chromaffin cells. Brain Res Bull 1998;46:245-251.
43. Nah SY, Park HJ, McCleskey EW: A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein. Proc Natl Acad Sci USA 1995;92:8739-8743.
44. Lin ZY, Chen LM, Zhang J, Pan XD, Zhu YG, Ye QY, Huang HP, Chen XC: Ginsenoside Rb1 selectively inhibits the activity of L-type voltage-gated calcium channels in cultured rat hippocampal neurons. Acta Pharmacol Sin 2012;33:438-444.
45. Lee JH, Jeong SM, Kim JH, Lee BH, Yoon IS, Choi SH, Lee SM, Park YS, Kim SS, Kim HC, Lee BY, Nah SY: Effects of ginsenosides and their metabolites on voltage-dependent Ca(2+) channel subtypes. Mol Cells 2006;21:52-62.
46. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, Stauderman KA, Cahalan MD: STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature 2005;437:902-905.
47. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina O, Kozak JA, Wagner SL, Cahalan MD, Velicelebi G, Stauderman KA: STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol 2005;169:435-445.
48. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Jr., Meyer T: STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol 2005;15:1235-1241.
49. Sweeney M, Yu Y, Platoshyn O, Zhang S, McDaniel SS, Yuan JX: Inhibition of endogenous TRP1 decreases capacitative Ca2+ entry and attenuates pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 2002;283:L144-155.
50. Ng LC, O'Neill KG, French D, Airey JA, Singer CA, Tian H, Shen XM, Hume JR: TRPC1 and Orai1 interact with STIM1 and mediate capacitative Ca(2+) entry caused by acute hypoxia in mouse pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2012;303:C1156-1172.
51. Ng LC, Ramduny D, Airey JA, Singer CA, Keller PS, Shen XM, Tian H, Valencik M, Hume JR: Orai1 interacts with STIM1 and mediates capacitative Ca2+ entry in mouse pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2010;299:C1079-1090.
52. Kunichika N, Yu Y, Remillard CV, Platoshyn O, Zhang S, Yuan JX: Overexpression of TRPC1 enhances pulmonary vasoconstriction induced by capacitative Ca2+ entry. Am J Physiol Lung Cell Mol Physiol 2004;287:L962-969.
53. Ogawa A, Firth AL, Smith KA, Maliakal MV, Yuan JX: PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2012;302:C405-411.
54. Remillard CV, Yuan JX: TRP channels, CCE, and the pulmonary vascular smooth muscle. Microcirculation 2006;13:671-692.
55. Jernigan NL, Herbert LM, Walker BR, Resta TC: Chronic hypoxia upregulates pulmonary arterial ASIC1: a novel mechanism of enhanced store-operated Ca2+ entry and receptor-dependent vasoconstriction. Am J Physiol Cell Physiol 2012;302:C931-940.
56. Jernigan NL, Paffett ML, Walker BR, Resta TC: ASIC1 contributes to pulmonary vascular smooth muscle store-operated Ca(2+) entry. Am J Physiol Lung Cell Mol Physiol 2009;297:L271-285.
57. Nunes P, Demaurex N: Redox regulation of store-operated Ca2+ entry. Antioxid Redox Signal 2014;21:915-932.
58. Lu JM, Weakley SM, Yang Z, Hu M, Yao Q, Chen C: Ginsenoside Rb1 directly scavenges hydroxyl radical and hypochlorous acid. Curr Pharm Des 2012;18:6339-6347.
59. Ohashi R, Yan S, Mu H, Chai H, Yao Q, Lin PH, Chen C: Effects of homocysteine and ginsenoside Rb1 on endothelial proliferation and superoxide anion production. J Surg Res 2006;133:89-94.
60. Yu J, Taylor L, Wilson J, Comhair S, Erzurum S, Polgar P: Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension. J Cell Physiol 2013;228:322-329.
61. Coe Y, Haleen SJ, Welch KM, Liu YA, Coceani F: The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb. J Pharmacol Exp Ther 2002;302:672-680.
62. Li H, Elton TS, Chen YF, Oparil S: Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994;266:L553-560.
63. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM, Naeije R: Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003;107:1329-1335.
64. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-2131.
65. DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF, Oparil S: ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995;269:L690-697.
66. Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S, Elton TS: Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994;77:1451-1459.
67. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA: Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res 2006;98:1528-1537.
68. Wang J, Chen Y, Lin C, Jia J, Tian L, Yang K, Zhao L, Lai N, Jiang Q, Sun Y, Zhong N, Ran P, Lu W: Effects of chronic exposure to cigarette smoke on canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol 2014;306:C364-373.
69. Song MY, Makino A, Yuan JX: STIM2 Contributes to Enhanced Store-operated Ca Entry in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension. Pulm Circ 2011;1:84-94.
70. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX: Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci USA 2004;101:13861-13866.
71. Zhang S, Patel HH, Murray F, Remillard CV, Schach C, Thistlethwaite PA, Insel PA, Yuan JX: Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry. Am J Physiol Lung Cell Mol Physiol 2007;292:L1202-1210.
72. Fernandez RA, Sundivakkam P, Smith KA, Zeifman AS, Drennan AR, Yuan JX: Pathogenic role of store-operated and receptor-operated ca(2+) channels in pulmonary arterial hypertension. J Signal Transduct 2012;2012:951497.